| Assessment Status | Rapid Review Complete |
| HTA ID | 23013 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
| Assessment Process | |
| Rapid review commissioned | 03/03/2023 |
| Rapid review completed | 21/04/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
